YCUB-6 BioVector®人 B 细胞前体白血病细胞株 Human B Cell Precursor Leukemia Cell Line

人 B 细胞前体白血病细胞系 YCUB-6 / Human B Cell Precursor Leukemia Cell Line YCUB-6

数据表 / Datasheet

细胞系信息

• 名称：BioVector® YCUB-6 细胞系

• 详细名称：人 B 细胞前体白血病细胞系 YCUB-6（携带 TCF3::PBX1 融合基因）

• 来源：2008 年建立，来源于一名 12 岁男孩复发急性淋巴细胞白血病（ALL）的外周血-1-2

• 细胞类型：B 细胞前体白血病（BCP-ALL）-1-2

• 形态：小而圆的细胞，悬浮生长，呈单细胞状态-1-2

• 免疫表型：CD3-、CD10+、CD13+、CD19+、CD20+、CD34-、CD37+、CD38+、CD80-、CD138+、HLA-DR+-1-2

• 主要遗传特征：经 RT-PCR 验证存在 TCF3::PBX1 融合基因（即 E2A::PBX1）-1-2

• 病毒检测：EBV-、HBV-、HCV-、HIV-1-、HIV-2-、HTLV-1/2-、MLV--1

• 支原体检测：PCR 检测阴性-1-2

• STR 鉴定：通过 ANSI/ATCC ASN-0002.1-2021 标准 STR 分析，STR 谱与参考数据库匹配-1-2

培养条件

• 培养基：BioVector® RPMI 1640 培养基，添加 10% BioVector® 胎牛血清-1-2

• 培养环境：37°C，5% CO₂，饱和湿度-1-2

• 传代方法：初始接种密度为 3 × 10⁶ 个细胞/mL；每周按 1:2 比例传代；保持细胞密度在 5–8 × 10⁶ 个细胞/mL（需保持高密度）-1-2

• 倍增时间：约 3–4 天-1-2

• 最大密度：约 6–8 × 10⁶ 个细胞/mL-1-2

• 冻存液：70% BioVector® RPMI 1640 培养基、20% BioVector® 胎牛血清、10% BioVector® DMSO-1-2

• 生物安全等级：BSL-1-1-2

特征与用途

• 携带 TCF3::PBX1 融合基因，是研究该融合基因在 B 细胞前体急性淋巴细胞白血病中致病机制的重要体外模型-1-2

• 该细胞系来源于复发患儿，对化疗药物敏感性研究具有重要价值；研究表明，YCUB-6 对苯达莫司汀联合克拉屈滨或阿糖胞苷具有协同至相加效应，可用于复发/难治性 ALL 的挽救治疗方案研究-5-6

• 在 NKX6-3 基因表达调控研究中，YCUB-6 作为 TCF3::PBX1 阳性细胞系被用于验证该融合基因对下游靶基因的调控作用-4

• 免疫表型为 CD19+、CD20+、CD34-，CD34 阴性提示该细胞系代表较为成熟的 pre-B 阶段，适用于 B 细胞分化及靶向 CD20 治疗研究-1-2

Cell Line Information

• Name: BioVector® YCUB-6 Cell Line

• Detailed Name: Human B Cell Precursor Leukemia Cell Line YCUB-6 (carrying TCF3::PBX1 fusion)

• Source: Established in 2008 from the peripheral blood of a 12-year-old boy with acute lymphoblastic leukemia (ALL) at relapse-1-2

• Cell Type: B cell precursor leukemia (BCP-ALL)-1-2

• Morphology: Small, round cells growing singly in suspension-1-2

• Immunophenotype: CD3-, CD10+, CD13+, CD19+, CD20+, CD34-, CD37+, CD38+, CD80-, CD138+, HLA-DR+-1-2

• Key Genetic Features: TCF3::PBX1 fusion gene verified by RT-PCR-1-2

• Virus Testing: PCR negative for EBV, HBV, HCV, HIV-1, HIV-2, HTLV-1/2, MLV-1

• Mycoplasma: Negative by PCR assay-1-2

• Authentication: STR analysis according to ANSI/ATCC ASN-0002.1-2021 standard resulted in an authentic STR profile matching the reference database-1-2

Culture Conditions

• Medium: BioVector® RPMI 1640 supplemented with 10% BioVector® fetal bovine serum-1-2

• Culture Environment: 37°C, 5% CO₂, humidified atmosphere-1-2

• Subculturing: Seed out initially at 3 × 10⁶ cells/mL; split 1:2 once a week; maintain high cell density at 5–8 × 10⁶ cells/mL-1-2

• Doubling Time: Approximately 3–4 days-1-2

• Maximum Density: Approximately 6–8 × 10⁶ cells/mL-1-2

• Cryopreservation: Frozen with 70% BioVector® RPMI 1640, 20% BioVector® fetal bovine serum, 10% BioVector® DMSO-1-2

• Biosafety Level: BSL-1-1-2

Characteristics & Applications

• Carries the TCF3::PBX1 fusion gene; serves as a critical in vitro model for studying the pathogenic mechanisms of this fusion in B-cell precursor acute lymphoblastic leukemia-1-2

• Derived from a relapsed pediatric patient; valuable for chemotherapy sensitivity studies. Research has demonstrated that YCUB-6 exhibits synergistic-to-additive effects when treated with bendamustine combined with cladribine or cytarabine, supporting its use in salvage therapy research for relapsed/refractory ALL-5-6

• Used in gene expression regulation studies, including investigations of NKX6-3 as a downstream target of TCF3::PBX1-4

• Immunophenotype CD19+, CD20+, CD34- (CD34 negative indicates a more mature pre-B stage); suitable for B-cell differentiation studies and CD20-targeted therapy research

BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心

电话:400-800-2947

工作QQ/微信同号:1843439339

网址

http://www.biovector.net